OMEROS CORP: insider trades · United States · SEC (Form 4)

About OMEROS CORP

Omeros Corp. is a U.S.-based biopharmaceutical company listed on the Nasdaq (United States), with headquarters in Seattle, Washington. Founded in 1994, the company was built around a discovery-and-development model focused on first-in-class therapeutics aimed at biologically complex pathways, especially complement-mediated disease, inflammation, oncology, and certain addictive or compulsive disorders. For French-, Belgian- and Swiss-based investors, Omeros fits the profile of a specialty biotech: high scientific optionality, meaningful regulatory and clinical execution risk, and a commercial story that is only now beginning to emerge. From a business-model standpoint, Omeros is not a diversified pharmaceutical conglomerate but a focused platform biotech with multiple proprietary programs. A core pillar is its complement pathway franchise, including MASP-2 inhibitor programs targeting diseases driven by complement dysregulation, notably TA-TMA and other rare or broader indications. The company’s pipeline also includes oncology assets such as OncotoX-AML, as well as OMS527, a program supported in part by NIDA funding for cocaine use disorder. In addition, Omeros references its T-CAT platform, which is being developed against multidrug-resistant pathogens. Competitively, Omeros occupies a niche position with potentially attractive barriers to entry because it is pursuing difficult, mechanism-based targets rather than “me-too” assets. That can translate into meaningful upside if a program gains clinical validation or commercial traction. At the same time, the investment case remains highly dependent on regulatory outcomes, reimbursement, and adoption speed. The launch of YARTEMLEA is therefore a pivotal development: according to the company, commercial distribution began in January 2026, and the product is the first approved treatment for TA-TMA. Omeros also states that a marketing authorization application is under review by the European Medicines Agency, with a decision expected in mid-2026. Geographically, Omeros remains primarily U.S.-anchored, both operationally and commercially, while also pursuing an international pathway through Europe. Its Seattle headquarters underscores its identity as a West Coast biotechnology company operating within a strong life-sciences ecosystem. Recent developments are important for investors tracking momentum and balance-sheet repair. In its first-quarter 2026 update, Omeros reported gross product sales of $11.1 million and net sales of $9.9 million for YARTEMLEA. Management also highlighted improved financial flexibility following a transaction with Novo Nordisk and the repayment of certain maturing notes. Overall, the stock presents a classic biotech mix: an emerging revenue base, a meaningful pipeline, and substantial clinical, regulatory, and financing risk, but also the potential for re-rating if execution continues to improve.